News | December 06, 2010

Cordis Enters Distribution Agreement for Ostial Stent Positioning System

December 6, 2010 – Cordis Corp. has entered into a distribution agreement with Ostial Solutions for the worldwide distribution of the Ostial Pro Stent Positioning System.

The Ostial Pro is the only aorto-ostial stent positioning system for coronary and peripheral applications. It is intended to optimize the treatment of patients who require a stent implantation for treatment for aorto-ostial blockages.

Aorto-ostial blockages occur at the origin of blood vessels arising from the aorta. This occurs in the right and left main coronary arteries, in coronary bypass grafts and in the renal arteries. These blockages comprise approximately 95 percent of all renal stent interventions and 8 percent of coronary stent interventions.

It is critical for the end of the stent to align precisely with the origin of the blood vessel in these cases. Using two-dimensional X-ray imaging and angiography is challenging, time-consuming and can lead to increased cost and length of procedures, as well as increased dye and radiation exposure. Imprecise positioning often requires the use of additional stents to treat the lesion and may increase risks of renarrowing.

“Ostial Pro is a simple solution to a principal challenge of aorto-ostial stent positioning by providing visual and tactile identification of the true ostium,” said Campbell Rogers, M.D., chief scientific officer and global head of research and development, Cordis. “The Ostial Pro facilitates precise stent implantation of aorto-ostial stents by identifying the true ostium. This can help make precise stent placement easier, safer and more predictable. This technology may reduce the need for additional stents and may reduce the risk of having to perform another intervention for restenosis. Based on these benefits, this simple device should become a standard element of aorto-ostial stenting.”

The stent is FDA-cleared and is currently being sold only in the United States by Ostial Solutions. Cordis plans to assume worldwide distribution in the first half of 2011.

For more information: www.cordis.com, www.ostialsolutions.net

Related Content

FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Sponsored Content | Videos | Angiography| June 22, 2017
Shimadzu Medical Systems highlighted new features of its Trinias Interventional X-ray line at the America College of
3d printing can aid procedural navigation in transcatheter tricuspid procedures
News | 3-D Printing| June 15, 2017
June 15, 2017 – Structural heart interventions are increasingly applied in patients with severe tricuspid regurgitati
Sponsored Content | Videos | Cardiovascular Ultrasound| June 15, 2017
Madhav Swaminathan, M.D., FASC, FAHA, clinical director of cardiothoracic anesthesiology, at Duke Univer
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Tryton Medical, Side Branch Stent, first U.S. commercial case, New York-Presbyterian Hospital, Columbia University Medical Center
News | Stents Bifurcation| March 31, 2017
Tryton Medical Inc. recently announced that the first U.S. commercial case using the Tryton Side Branch Stent was...
Sponsored Content | Videos | Stents Bioresorbable| March 30, 2017
Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, discusses t
Overlay Init